The current situation of cancer morbidity and mortality in the light of the National Cancer Registry, Hungary. Prostate ; — Molecular pathology of prostate cancer. Molecular subtypes and perspectives of targeted therapies in prostate cancer.
Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer. Integrative clinical genomics of advanced prostate cancer.
Cell ; — Germline and somatic mutations in prostate cancer for the clinician. J Natl Compr Canc Netw.
Description Summary: Objective To conduct a central pathology review within a randomized clinical trial on salvage radiation therapy RT in the presence of biochemical recurrence after prostatectomy to assess whether this results in changes in histopathological prognostic factors, such as Gleason score. Gleason score, tumour classification and resection margin status were reassessed and compared with the results of local pathology review. Agreement was assessed using contingency tables and Cohen's kappa coefficient.
Germline genetic testing in prostate cancer — further enrichment in variant histologies? Oncoscience ; 5: 62— Inherited DNA-repair gene mutations in men with metastatic prostate cancer.
N Engl J Med. Eur Urol. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
J Clin Oncol. J Clin Oncol ; — Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer.
The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer ; — Medical treatment options in BRCA-associated cancers.
Genomic analysis of three metastatic prostate pathology of prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency.
Version 2. Mutations in BRCA2 and taxane resistance in prostate cancer. Sci Rep.
Subjects must meet all of the following criteria to be enrolled in this study: 1. Male aged 21 years or older. Ability to provide signed informed consent and willingness to comply with protocol requirements.